Coagulation and fibrinolysis were studied in patients with acute myocardial infarction during intravenous infusion of recombinant human tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 90 min, n = 101), streptokinase (1,500,000 IU over 60 min, n = 61), or placebo (n = 40). In the rt-PA group, the plasma level of rt-PA antigen was 1.2 + 0.6 gig/ml (mean + SD) and the euglobulin fibrinolytic activity (EFA) was 910 735 IU t-PA/ml. In the streptokinase group, the EFA was equivalent to 430 + 435 IU t-PA/ml. At the end of the infusion, the plasma fibrinogen level measured with a coagulation rate assay was decreased to 57 ± 33% of the preinfusion value in the rt-PA group, to 7 + 10% in the streptokinase group, and remained unchanged in the placebo group. Fibrinogen-fibrin degradation products increased to 0.75 + 0.54 mg/ml in the streptokinase group but to only 0.10 ± 0.13 mg/ml in the rt-PA group. The plasma levels of a2-antiplasmin, plasminogen, and factor V decreased to between 30% and 45% in the rt-PA group but significantly more in the streptokinase group (to between 15% and 25%). Thus rt-PA induced much less systemic fibrinolytic activation than streptokinase. In the patients who received rt-PA, a weak correlation (r = .21, n = 89, .1 > p > .05) was found between the extent of fibrinogen breakdown at 90 min and the plasma rt-PA concentration. Fibrinogen breakdown was significantly higher (p < .05) in patients with successful recanalization (decrease to 52 + 32%, n = 61) than in unresponsive patients (decrease to 69 ± 35%, n = 22). The plasma rt-PA concentration in patients with successful recanalization was 1.4 ± 0.7 gg/ml, and that in unresponsive patients was 1. 1 ± 0.7 gg/ml (p > . 1).
coronary reperfusion rate of about 75% but reported some degree of systemic fibrinogen breakdown (>15%) in six out of 40 evaluated patients. 7 Two European multicenter studies comparing rt-PA and streptokinase or rt-PA and placebo were carried out to further substantiate the efficacy and clot specificity of rt-PA. The core results of these trials are reported elsewhere.8 9 Here we report detailed results of analyses of relevant components of coagulation and fibrinolysis obtained during the intravenous infusion of rt-PA, streptokinase, or placebo in the patients of these clinical trials. These results obtained in the rt-PA groups of both studies are pooled because the two studies were carried out simultaneously by the same protocol, all analyses of the samples were performed in the same core laboratory, and separate analysis of the results obtained in the two rt-PA groups has revealed no significant differences.
Methods
The study protocols applied to the patients with evolving myocardial infarction are reported elsewhere. 8' 9 Briefly, 129 patients with acute myocardial infarction were randomly assigned to intravenous infusion of either rt-PA (64 patients) or streptokinase (65 patients). 8 Alternatively, patients were randomly assigned to intravenous infusion of either rt-PA (64 patients) or placebo (65 patients).9 The dose of rt-PA was 0.75 mg/kg over 90 min' 9 and that of streptokinase was 1,500,000 IU over 60 min.8 All patients also received 5000 IU of heparin intravenously before the start of the infusion. The study protocols were approved by the internal review boards of the participating centers and were carried out in compliance with the Declaration of Helsinki. The data reported here were obtained in 101 patients treated with rt-PA, 61 patients treated with streptokinase, and 40 patients with placebo. Judgment on reperfusion was based on the patency of vessels in the posttreatment angiogram, the appearance of vessels, in particular the presence of intraluminal thrombus, and knowledge of the presumed infarctrelated vessel as determined by the electrocardiogram.8
Blood (9 vol) was collected on citrate (1 vol) (final concentration O.OM) or on citrate containing aprotinin (Trasylol; Bayer, Leverkusen, West Germany) (final concentration 150 kIU/ml) before and 60 and 90 min after the start of the infusion. The plasma samples obtained by centrifugation within 1 hr were stored at -200 C. The following assays were performed on plasma collected on aprotinin: fibrinogen level, determined by a modified'0 version of the clotting rate assay of Clauss" and by the sodium sulfite precipitation method'2; fibrinogen-fibrin degradation product (FDP)13; t-PA antigen,* determined by an immunoradiometric assay'5; prothrombin time; activated partial thromboplastin time; and factor V. Interference of heparin in these assays is minimized by 10-fold dilution of the sample in the clotting rate assay for fibrinogen and in the factor V assay. The clotting procedure on samples for the assay of FDP was performed twice to eliminate residual unclotted fibrinogen.
Euglobulin fibrinolytic activity (EFA) on fibrin plates,'6 plasminogen,'7 and a2-antiplasminl' were determined on plasma collected without aprotinin. The values of the prothrombin time, a2-antiplasmin, plasminogen, and factor V were expressed in percent by comparison with a standard curve obtained by serial dilutions of a normal plasma pool.
Statistical analysis was performed by two-way analysis of variance followed by Tukey's t test for the comparison of the plasma levels in samples taken at different times or by unpaired Student's t test for the comparison of the drug regimen. 19 Linear regression was applied for correlation of the different factors. Unless stated otherwise, data are given as mean + SD.
Results
Intravenous infusion of rt-PA resulted in a steadystate rt-PA plasma concentration of 1.2 ± 0.6 ,ag/ml (n = 93) after 60 min of infusion. The corresponding rt-PA activity assessed as plasma EFA on fibrin plates was 910 ± 735 IU t-PA/ml. The correlation between these two variables (r -.49, n = 90, p < .001) (figure 1) was reasonably good, in view of the relative inaccuracy of the EFA assay. In the streptokinasetreated group, the EFA after 60 min of infusion was equivalent to 430 + 435 IU t-PA/ml. PLASMA rt-PA ANTIGEN (pggmi) FIGURE 1. Correlation between plasma rt-PA antigen concentration (ug/ml) and EFA (IU of t-PA/ml) 60 min after the start of the infusion. r = .49 (p < .001).
Intravenous infusion of rt-PA was associated with a decrease of the plasma fibrinogen level to 57 + 33% at 90 min, when assessed with a clotting rate assay (figure 2, A). After intravenous infusion of streptokinase, the fibrinogen levels dropped to 11 + 18% of the baseline level at the end of the 60 min of infusion and to 7 ± 10% 30 min later. In the placebo group, the fibrinogen breakdown was negligible. The extent of fibrinogenolysis was significantly (p < .001) more pronounced in the streptokinase-treated group than in the rt-PA-treated group. Fibrinogen breakdown appeared to be less extensive when fibrinogen was assayed by sodium sulfite precipitation'2 (table 1), which assesses both rapidly coagulable fibrinogen and slowly clottable early FDPs such as fragments X and Y.
After 60 min of infusion, the fibrinogen level as measured with the clotting rate assay had dropped to below 1.0 g/liter in nine of 89 patients (10%) of the rt-PA group and in 50 of 56 patients (89%) of the streptokinase group. Ninety minutes after the start of the infusion, the corresponding figures were 24 of 89 patients (27%) in the rt-PA group and 54 of 57 (95%) in the streptokinase group. After 60 min of infusion, only one patient had a fibrinogen level below 0.5 g/liter in the rt-PA group compared with 48 (86%) in the streptokinase group. The corresponding figures at 90 min were 10 of 89 (1 1 %) after rt-PA and 53 of 57 (92%) after streptokinase.
FDPs increased to 0.75 ± 0.54 mg/ml in the streptokinase group (n = 53) but only to 0.10 + 0.13 mg/ml in the rt-PA group (n = 91) and 0.02 0.06 mg/ml in the placebo group (n = 37). These levels represent about 30% of the baseline fibrinogen level of 2.6 g/liter in the streptokinase group and about 4% and 1% in the rt-PA (baseline fibrinogen 2.7 g/liter) and the placebo (baseline fibrinogen 2.8 g/liter) groups, respectively (figure 2, B). Figure 3 shows the changes in a,-antiplasmin and plasminogen. After 60 min of infusion, a2-antiplasmin decreased to 31 + 23% in the rt-PA group and 25 ± 24% in the streptokinase group. After 90 min, the respective values were 33 + 21% and 25 + 20%. Although the decrease of a2-antiplasmin was extensive in both groups, it was significantly (p < .05) greater in the streptokinase group. No changes were observed in the placebo group. At 60 min the plasminogen levels were decreased to 40 ± 18% in the rt-PA group and to 22 ± 21% in the streptokinase group. The corresponding values at 90 min were 39 ± 19% and 18 ± 16%.
The difference between the two drug regimens was highly significant (p < .001). It must be pointed out that the a2-antiplasmin and plasminogen levels were assayed on plasma samples taken on citrate only. In such samples in vitro activation of plasminogen and consumption of a2-antiplasmin is to be expected.20
The changes in factor V levels and in prothrombin time are represented in figure 4. In the rt-PA group, factor V decreased from 75 ± 19% (baseline) to 64 ± 27% and 45 ± 22% after 60 and 90 min of infusion, respectively. In the streptokinase group, factor V dropped from 77 ± 21% (baseline) to 32 ± 16% and 25 ± 15% at 60 and 90 min, respectively. A decrease was also observed in the placebo group from 72 ± 22% (baseline) to 71 ± 24% at 60 min and to 58 ± 23% at 90 min. The prothrombin time (expressed as percent) showed similar changes. In the rt-PA group, it dropped from 71 ± 28% (baseline) to 44 ± 29% and to 31 ± 19% at 60 and 90 min, respectively. The corresponding values in the streptokinase group were 76 27% (baseline), 21 + 13% (60 min), and 20 16% (90 min). A decrease was also observed in the placebo group from 73 ± 30% (baseline) to 45 + 22% (60 min) and 40 + 23% (90 min). The changes observed in the factor V levels and in the prothrombin times were at least in part caused by interference in the assays of heparin, which was infused in high doses in all patients. This is confirmed by a prolongation of the activated partial thromboplastin time (APTT) in the three groups. In the placebo group, the APTT rose from 55 sec (median) (range 36 to more than 180) to 122 sec (41 to more than 180) at 60 min and 128 sec (37 to more than 180) at 90 min. The corresponding values in the rt-PA group were 60 sec (38 to more than A 100 0 180) (baseline), 101 sec (40 to more than 180) (60 min), and 125 sec (44 to more than 180) (90 min). In the streptokinase group, the baseline APTT was 60 sec (39 to more than 180) but exceeded 180 sec at 60 and 90 min. At 90 min the APTT was more than 180 sec in 12 of 36 patients (33%) in the placebo group, in 28 of 87 patients (32%) in the rt-PA group, but in 41 of 52 (79%) streptokinase-treated patients. There was only a weak overall correlation between the fibrinogen breakdown and the plasma steady-state concentration of rt-PA (r .21, n = 89, .1 > p > .05) ( figure 5 ). This trend toward more extensive fibrinogenolysis with an increasing plateau level of rt-PA is presented in table 2. The steady-state plasma concentrations of rt-PA were slightly higher in the subgroup of patients with successful coronary recanalization as compared with the unresponsive patients, but this difference was not statistically significant (table 3). At the end of the rt-PA infusion, the residual fibrinogen levels were significantly (p < .05) lower in the subgroup with recanalization than in the subgroup of unresponsive patients (table 3) . However, there was no significant correlation between recanalization and plasma rt-PA concentration (table 2). 
Discussion
These results confirm that intravenous infusion of rt-PA in patients with acute myocardial infarction is relatively fibrin-specific as compared with streptokinase and provide additional information on the extent and limits of this fibrin specificity.
A reasonably good correlation was observed between rt-PA antigen levels and fibrinolytic activity, indicating that most of the rt-PA antigen circulates as free and active rt-PA. With the singular infusion rate of 0.75 mg/kg rt-PA over 90 min, a mean plasma steadystate concentration of rt-PA antigen of 1.2 gg/ml was reached. This concentration is about 1000 times higher than the baseline level in healthy subjects. 15 However, the individual response to this standard infusion was quite variable, as indicated by the large standard deviation (0.6 ug/ml), which implies that the rt-PA concentration in the plasma of individual patients cannot be predicted accurately. Because the clearance of rt-PA occurs via the liver,2' this interindividual variability may be caused by variable liver flow in these acutely ill patients. Interindividual variability in plasma rt-PA levels and tl/2 of more than twofold have previously been observed in patients suffering from various pathologic conditions.20
The extent of fibrinogen breakdown measured by a coagulation rate assay during infusion of rt-PA, although much less pronounced than that during administration of streptokinase, is occasionally very significant. A decrease below 1.0 g/liter was observed in 27% of the rt-PA-treated patients at the end of the 90 min infusion. This fibrinogenolysis is apparently more extensive that that reported in the first trial of rt-PA in myocardial infarction.7 In that study, however, fibrinogen was assayed by different methods, including assays that are less sensitive to limited fibrinogen degradation.20' 22 The fibrinogenolysis was less pronounced when fibrinogen was assayed by sulfite precipitation than with the clotting rate assay, a finding that is in agreement with previous reports.20 22 This suggests that the fibrinogen degradation during infusion of rt-PA results in large amounts of early degradation products belonging to the fragment X and/or fragment Y groups,23 which are only slowly coagulable and therefore not measured in fibrinogen assays based on coagulation rate. This hypothesis is further substantiated by the finding of only 4% of the initial fibrinogen level as incoagulable FDPs. Fragments X and Y, indeed, are not recovered in serum that is used for FDP assay. Tiefenbrunn et al. 24 have reported data obtained in a subset of patients of the first rt-PA trial7 that are consistent with this interpretation. These authors reported an only slight decrease of fibrinogen (about 15%) in 12 patients showing an rt-PA plasma concentration of 1.7 ,g/ml (compared with the International Reference Preparation for t-PA 83/517'4) by using the fibrinogen assay based on sulfite precipitation. In addition, degradation of fibrinogen in vitro during freezing and thawing of samples containing high levels of rt-PA cannot be entirely excluded even in the presence of aprotinin, which prevents fibrinogen breakdown in vitro markedly but incompletely. Although the extent of fibrinogen degradation found during rt-PA infusion in the present study might have been caused in part by fibrinogen breakdown in vitro, we have obtained conclusive evidence, by performing fibrinogen assays on whole blood immediately after collection,20 that extensive activation of the fibrinolytic system in vivo associated with significant fibrinogen breakdown does occur in some patients subjected to infusion of rt-PA at such a high rate as used in the present study. Recently, Holvoet et al. 25 described a monoclonal antibody that prevents binding of t-PA to fibrin and that inhibits fibrinogen degradation by high concentrations of rt-PA in plasma in vitro. This monoclonal antibody could be useful to discriminate between fibrinogen degradation in vitro and in vivo during infusion of rt-PA. Although a borderline significant correlation (.1 > p > .05) was observed between the extent of fibrinogen breakdown and the plasma rt-PA concentration, some patients showed no fibrinogen breakdown in spite of very high rt-PA levels, whereas others had extensive fibrinogenolysis in the presence of relatively low concentrations of rt-PA ( figure 5 ). It is possible that some patients suffered low-grade, compensated, intravascular coagulation and that the presence of fibrin in the microcirculation was responsible for the systemic fibrinolytic activation. However, to confirm this hypothesis, specific assays to discriminate fibrin degradation products from fibrinogen fragments are required. 516 The extensive decrease in ca2-antiplasmin and plasminogen levels during infusion of rt-PA was probably largely due to activation in vitro of the fibrinolytic system by rt-PA, which is enhanced by the freezing and thawing of plasma samples (unpublished observations). The samples used for these assays were not collected on aprotinin because this protease inhibitor would interfere with the assay. Degradation in vitro of a2-antiplasmin and plasminogen in samples obtained during infusion of rt-PA is further substantiated by the observation that the levels of plasminogen and a2-antiplasmin were two times higher 30 min after the end of the infusion (when the rt-PA concentrations were very low) than at the end of the infusion.20 Such a rapid rise, indeed, cannot be caused by synthesis of these proteins.
Although the extent of systemic activation of the fibrinolytic system in vivo by rt-PA observed in this study is probably somewhat overestimated because of activation of the fribrinolytic system and fibrinogen breakdown in vitro in plasma samples containing a high concentration of rt-PA,3 20 some degree of systemic fibrinolytic activation was to be expected on the basis of the kinetic parameters of the plasminogen activation by t-PA26: the rate of plasmin formation may be represented by v = (kca/Km)) [ The changes in factor V and prothrombin time are probably influenced to some extent by the simultaneous infusion of heparin, as can be seen from the changes in the placebo group. Whereas no clinically relevant difference in these parameters was observed between the rt-PA group and the placebo group, the more extensive changes in the streptokinase group further confirmed that infusion of streptokinase is associated with a general breakdown of the hemostatic system.
Addendum
In this study, the level of t-PA antigen and activity have been expressed by comparison with the International Reference Preparation for t-PA (83/157). 14 This standard exhibits a specific activity of 500,000 IU/mg. We have previously expressed the t-PA activity by comparison with the International Reference Preparation of Urokinase (66/46) and found specific activities of about 100,000 lU/mg.27 Thus, 1 IU of t-PA obtained by com-CIRCULATION parison with the new t-PA standard corresponds to 0.2 IU of our previous units obtained by calibration with the urokinase standard. By means of an immunoradiometric assay, calibrated with a protein assay and a specific standard,15 1 mg of t-PA referenced to the new t-PA standard corresponds to 2 mg of t-PA referenced to our previously used homemade reference mt-PA. Therefore, all values of EFA in the present study are about five times higher and all values of t-PA antigen two times lower than would have been obtained with our homemade standard. The homemade standard was used for calibration of t-PA antigen concentrations in several previously published studies. 2-5, 21, 24 The international standard is used for calibration in more recent studies. 8, 9, 20 
